Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Rhea-AI Summary
Profound (NASDAQ:PROF) reported its year-end TULSA-PRO installed base reached 78 systems as of December 31, 2025, exceeding its goal of 75 installs for 2025. The company also said its qualified sales pipeline grew to 97 new systems classified in the "Verify, Negotiate and Contracting" stages at year-end. Management linked the larger installed base to expectations of higher patient treatment rates and growth in recurring revenue tied to procedures, and noted upcoming Q4 and full-year 2025 financial results due near the end of February 2026.
Positive
- Installed base reached 78 systems as of Dec 31, 2025, above goal
- Qualified pipeline grew to 97 new systems in late-stage sales
Negative
- None.
News Market Reaction – PROF
On the day this news was published, PROF gained 2.49%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PROF was down 0.47% with mixed moves among peers: OWLT (-0.94%), RPID (-4.28%), SERA (-1.86%) declined while RCEL (+3.03%) and LNSR (+0.09%) rose, supporting a stock-specific interpretation of this news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Commercial adoption | Positive | -0.5% | First commercial TULSA-PRO prostate cancer case at Johns Hopkins Medicine. |
| Dec 30 | Private placement close | Negative | -0.1% | Closed private placement of 921,428 shares at US$7.00 for US$6.45M. |
| Dec 24 | Financing upsize | Negative | +1.5% | Upsized private placement to raise up to US$6.45M at US$7.00 per share. |
| Dec 23 | Registered offering close | Negative | +0.8% | Closed $36M registered direct offering of 5,142,870 shares at $7.00. |
| Dec 19 | Financing announcement | Negative | -2.9% | Announced up to $40M financing via $36M offering and $4M placement. |
Recent news shows mixed alignment: positive adoption and distribution milestones sometimes coincided with share declines, while dilution-related financings produced both selloffs and rallies.
Over the past month, Profound executed multiple financings, including a $36 million registered direct offering and a private placement of 921,428 shares for about $6.45 million, to support sales, marketing, R&D, and strategic transactions. Concurrently, commercial progress included Johns Hopkins Medicine’s first commercial TULSA-PRO case and new exclusive distribution agreements in several regions. A Form S-3 shelf for up to $150,000,000 of securities and a Q3 2025 going-concern disclosure frame today’s installed base milestone within a capital-intensive growth strategy.
Regulatory & Risk Context
On Nov 13, 2025, Profound filed a Form S-3 shelf registration to offer up to $150,000,000 of various securities. As of the provided data, the shelf was not yet effective and had 0 recorded usages, but it establishes capacity for future capital raises that could impact existing shareholders depending on structure and timing.
Market Pulse Summary
This announcement highlights that Profound exceeded its 2025 TULSA-PRO installed base target with 78 systems versus a goal of 75, and ended the year with a qualified pipeline of 97 additional systems. In the months prior, the company raised capital through a $36 million registered offering and other placements and filed a $150,000,000 shelf, against a backdrop of growing revenue but continued net losses. Investors may watch upcoming 2025 financial results and further adoption metrics to gauge operating leverage.
Key Terms
mri-guided medical
ablation medical
AI-generated analysis. Not financial advice.
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems
TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than its previously announced goal of 75 installs by the end of 2025.
Profound’s TULSA-PRO qualified sales pipeline also grew to 97 new systems being classified within one of the “Verify, Negotiate and Contracting” stages at year-end.
“As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” said Profound’s CEO and Chairman, Arun Menawat. “That is being driven primarily by the TULSA Procedure’s ability to treat an unrivaled range of prostate diseases, severities, and aggressions, while preserving crucial functions like continence and sexual health of the patient. We look forward to releasing our fourth quarter and full year 2025 financial results near the end of February 2026.”
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This press release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195
FAQ
How many TULSA-PRO systems did Profound (PROF) have installed at year-end 2025?
Did Profound (PROF) meet its 2025 TULSA-PRO installation target?
What size was Profound's (PROF) qualified sales pipeline at year-end 2025?
When will Profound (PROF) release its Q4 and full-year 2025 financial results?
What did Profound (PROF) say the larger installed base could mean for shareholders?
